iMRI-guided surgery
DeviceFor iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
NCT Number: NCT02379572
Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies.
Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival.
The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany, Bonn, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Time frame: 48 hour
Completeness of resection in the postoperative MRI within 48h after surgery. Blinded analysis by an independent radiologist.
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
-KPS clinical scoring
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
-NIHSS stroke score
Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery
-quality of life (EORTC) questionnaire
Time frame: Time of hospital stay (average 7days)
-ICU and overall hospital stay after surgery
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
-adjuvant treatment each patient has received
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
-recurrent tumor growth (RANO criteria) according to local tumor boards and independent blinded analysis
Time frame: 3Months, 6Months, 9Months, 12Months after surgery
-follow-up imaging 3, 6, 9, 12 months postoperative incl. independent blinded analysis
Time frame: 1 week after surgery
Histological analysis
Time frame: 1 week after surgery
MGMT promoter analysis (Routine molecular diagnostics)
Time frame: 1 week after surgery
IDH-1 mutation analysis (Routine molecular diagnostics)
Time frame: Day of surgery - 6 months - 12 months
6M&12M-PFS
Time frame: Day of surgery - Death of patient (Max. 10 years follow-up)
OS of patients
Time frame: Blinded analysis of preoperative imaging (not older than 3 days prior to surgery)
Independent blinded analysis of the preoperative imaging data by a blinded neurosurgeon with extensive experience in the resection of gliomas. Analysis will be done before the final evaluation of results. (Within 12 months)
University Hospital Tuebingen
Other
Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01339052
Astrocytoma, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT02902757
Astrocytoma, Glioblastoma
Los Angeles, California, United States
View Trial DetailsNCT05635734
Astrocytoma, Glioblastoma
Barcelona, Spain
View Trial DetailsNCT03477513
Astrocytoma, Glioblastoma
Philadelphia, Pennsylvania, United States
View Trial Details